EFFICACY OF BENZONIDAZOLE IN THE SURVIVAL OF IMMUNOSUPPRESSED PATIENTS DUE TO REACTIVATION OF CHAGAS DISEASE
DOI:
https://doi.org/10.56238/arev7n8-234Keywords:
Chagas Disease (CD), Trypanosoma cruzi, Immunosuppressed Patients, Reactivation, BenzonidazoleAbstract
Chagas disease (CD) is more prevalent in tropical and humid regions. The disease remains a public health problem in several regions of the world, particularly in endemic areas, as observed in several South American countries. Drug treatment in the acute phase of the disease is effective but has limitations related to tolerance, which worsens in immunosuppressed patients. Therefore, this study aimed to evaluate the relationship between benznidazole intervention in immunosuppressed patients and survival prognosis. To achieve this objective, a secondary study was conducted through a systematic literature review. The Medline/pubmed and Scielo databases were searched without date or language restrictions. The variables evaluated included the clinical presentation for different types of immunosuppression, the pattern of CD reactivation in immunosuppressed patients, and its relationship with the use of other forms of intervention such as ketoconazole, benznidazole, and nifurtimox. Few studies were eligible for retraction regarding the relationship between CD and immunosuppression and pharmacological intervention with benznidazole, but four case reports and two reviews were available. The data evaluated demonstrate that intervention can vary depending on the symptomatology and/or clinical presentation of the patients. Regarding the efficacy of benznidazole, indicated as primary prophylaxis, of the four clinical cases reported, two (50%) resulted in death. Other factors were certainly linked to patient outcomes, such as age, timing of early or late diagnosis, severity of the clinical presentation, and use of primary and secondary prophylaxis. However, this approach generated a consistent indicator of the need for new approaches that interpret the diverse symptoms and clinical manifestations of CD in immunosuppressed patients and may lead to the emergence of new, more assertive protocols for disease intervention.
Downloads
References
LIMA, M. M.; COSTA, V. M. da; PALMEIRA, S. L.; CASTRO, A. P. B. de. Estratificação de territórios prioritários para vigilância da doença de Chagas crônica: análise multicritério para tomada de decisão em saúde. Cadernos de Saúde Pública, v. 37, n. 6, 2021. Disponível em: https://doi.org/10.1590/0102-311X00175920. Acesso em: 22 ago. 2025.
SALVADOR, F. et al. Immunosuppression and Chagas disease; experience from a non-endemic country. Clinical Microbiology and Infection, v. 21, n. 9, p. 854–860, 2015. Disponível em: https://doi.org/10.1016/j.cmi.2015.05.033. Acesso em: 22 ago. 2025.
MUNIZ, R. C. Efeito do tratamento do benzonidazol e da terapia antioxidante na cardiopatia chagásica crônica. 2009. Disponível em: https://repositorio.ufsc.br/handle/123456789/92447?show=full. Acesso em: 15 jun. 2023.
CLARA, M. et al. Reativação da infecção por Trypanosoma cruzi em paciente com síndrome de imunodeficiência adquirida. Revista da Sociedade Brasileira de Medicina Tropical, v. 32, n. 3, p. 291–294, 1999. Disponível em: https://doi.org/10.1590/S0037-86821999000300011. Acesso em: 22 ago. 2025.
OLIVEIRA, L. et al. Reativação da doença de Chagas com envolvimento do sistema nervoso central durante tratamento de linfoma não Hodgkin. Revista Brasileira de Hematologia e Hemoterapia, v. 32, n. 3, p. 269–272, 2010. Disponível em: https://doi.org/10.1590/S1516-84842010005000080. Acesso em: 22 ago. 2025.
BUCCHERI, R. et al. Chagasic meningoencephalitis in an HIV infected patient with moderate immunosuppression: prolonged survival and challenges in the HAART era. Revista do Instituto de Medicina Tropical de São Paulo, v. 57, n. 6, p. 531–535, 2015. Disponível em: https://doi.org/10.1590/S0036-46652015000600014. Acesso em: 22 ago. 2025.
CHALELA, C. M. et al. Relato de caso: Reativação da doença de Chagas após transplante autólogo de células-tronco hematopoéticas. Sociedade Brasileira de Medicina Tropical, 2020. Disponível em: https://sbmt.org.br/relato-de-caso-reativacao-da-doenca-de-chagas-apos-transplante-autologo-de-celulas-tronco-hematopoeticas/. Acesso em: 15 jun. 2023.
CAROD-ARTAL, F. J. American trypanosomiasis. In: Neurological Aspects of Tropical Disease. p. 103–123, 2013. Disponível em: https://doi.org/10.1016/B978-0-444-53490-3.00007-8. Acesso em: 22 ago. 2025.
PINAZO, M. et al. Immunosuppression and Chagas disease: a management challenge. PLoS Neglected Tropical Diseases, jan. 2013. Disponível em: https://doi.org/10.1371/journal.pntd.0001965. Acesso em: 22 ago. 2025.
BIBLIOTECA VIRTUAL EM SAÚDE. Como devo proceder frente a um paciente com Doença de Chagas na fase crônica ou indeterminada da doença? Disponível em: https://aps-repo.bvs.br/aps/como-devo-proceder-frente-a-um-paciente-com-doenca-de-chagas-na-fase-cronica-ou-indeterminada-da-doenca. Acesso em: 15 jun. 2023.
ORGANIZACIÓN PANAMERICANA DE LA SALUD. Tratamiento etiológico de la enfermedad de Chagas: conclusiones de una consulta técnica. Genebra: OPAS, 1998. Disponível em: http://cidbimena.desastres.hn/filemgmt/files/tratamientochagas.pdf. Acesso em: 22 ago. 2025.
CONSENSO BRASILEIRO EM DOENÇA DE CHAGAS. Revista da Sociedade Brasileira de Medicina Tropical, v. 38, supl. 3, p. 7–29, 2005. Disponível em: ftp://ftp.cve.saude.sp.gov.br/doc_tec/ZOO/chagas05_consenso_svs.pdf. Acesso em: 22 ago. 2025.
FUNDAÇÃO OSWALDO CRUZ. Pesquisa avalia benefício do benzonidazol na doença de Chagas. Rio de Janeiro: Fiocruz, jan. 2019. Disponível em: https://portal.fiocruz.br/noticia/pesquisa-avalia-beneficio-do-benzonidazol-na-doenca-de-chagas. Acesso em: 22 ago. 2025.
JOSÉ, E. et al. Elevated IL-17 levels and echocardiographic signs of preserved myocardial function in benznidazole-treated individuals with chronic Chagas’ disease. International Journal of Infectious Diseases, v. 79, p. 123–130, 2019. Disponível em: https://doi.org/10.1016/j.ijid.2018.11.369. Acesso em: 22 ago. 2025.
